Clinical trials: Double Incontinence
Urinary Incontinence, Stress
An 8 Week Study Looking At The Efficacy, Toleration And Safety Of SS-RBX For Stress Urinary Incontinence.
A study designed to assess the efficacy, toleration and safety of SS-RBX for the treatment of stress urinary incontinence.
- Trial name
- NCT00138749
- Testing
- SS-RBX
- Where
- 95 sites in United States, Canada
- Volunteers
- 402 people
- Sponsor
- Pfizer
Chronic Cough
Efficacy and Safety of Gefapixant (MK-7264) in Women With Chronic Cough and Stress Urinary Incontinence (MK-7264-042)
The purpose of this study is to evaluate the efficacy and safety of gefapixant, in improving symptoms of cough-induced stress urinary incontinence (SUI) in adult female participants with refractory or unexplained chronic cough.
- Trial name
- NCT04193176
- Testing
- Gefapixant
- Where
- 90 sites in United States, Argentina and 10 more
- Volunteers
- 376 people
- Sponsor
- Merck Sharp & Dohme LLC
Faecal Incontinence
Safety and Tolerability of the Twice Daily Intra-anal Application of NRL001 Cream for 14 Days
The study is being conducted to evaluate the safety and tolerability after single and repeated twice daily intra-anal applications of 1mL NRL001 cream in stepwise increasing concentrations.
- Trial name
- NCT06593730
- Testing
- NRL001 cream 0.5%w/w, NRL001 cream 0.75%w/w, NRL001 cream 1.0%w/w
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Norgine
Urinary Incontinence
A Study to Measure the Effect of Tolterodine Extended Release on the Thickness of the Bladder Wall in Patients With Overactive Bladder
The main aim of the study is to investigate whether taking Tolterodine for overactive bladder symptoms can reduce the thickness of the bladder wall, as measured by intra-vaginal ultrasound.
- Trial name
- NCT00137397
- Testing
- Tolterodine ER
- Where
- 11 sites in United Kingdom
- Volunteers
- 80 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Urinary Bladder, Overactive
A Study to Compare the Effectiveness and Safety of Fesoterodine and Placebo in an Elderly Population of Patients Who go to the Toilet Very Frequently Due to Overactive Bladder.
The drug being studied, fesoterodine fumarate helps prevent the bladder neck opening at unwanted times and has been shown to help patients with overactive bladder syndrome pass urine less frequently than before treatment.
- Trial name
- SOFIA (NCT00798434)
- Testing
- Fesoterodine fumarate
- Where
- 60 sites in Austria, Belgium and 13 more
- Volunteers
- 794 people
- Sponsor
- Pfizer
Stress Urinary Incontinence (SUI)
Stress Urinary Incontinence for Female Patients (CGM MUIT-2301)
This study is a multicenter, prospective, randomized, double-blind, sham-controlled clinical trial conducted in female patients with stress urinary incontinence.
- Trial name
- NCT07440927
- Testing
- Ceragem Innerfit medi-tech
- Where
- South Korea
- Volunteers
- 96 people
- Sponsor
- Ceragem Clinical Inc.
Urinary Incontinence
A Study to Assess Efficacy and Safety With Solifenacin Succinate to Improve Urinary Continence After Robotic Assisted Radical Prostatectomy
The purpose of this study is to assess the efficacy and safety of 12 weeks of treatment of solifenacin succinate versus placebo in participants who are incontinent after Robotic Assisted Radical Prostatectomy.
- Trial name
- NCT01371994
- Testing
- solifenacin succinate
- Where
- 60 sites in United States, Canada
- Volunteers
- 640 people
- Sponsor
- Astellas Pharma Inc
Neurogenic Detrusor Overactivity
Intravesical Injection of Botulinum Toxin A Versus Saline for Neurogenic Detrusor Overactivity
This is a prospective, multicentre (7 sites), randomized, double-blind, study comparing intravesical injection of BOTOX to placebo in 56 subjects with NDO secondary to spinal cord injury or multiple sclerosis.
- Trial name
- NCT01091727
- Testing
- Botulinum toxin A
- Where
- Canada
- Volunteers
- 57 people
- Sponsor
- Sunnybrook Health Sciences Centre
Urinary Bladder, Overactive
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
The study is intended to test efficacy, safety and tolerability of two doses of once daily (qd) Mirabegron against placebo to treat patients with symptoms of overactive bladder.
- Trial name
- CAPRICORN (NCT00912964)
- Testing
- Mirabegron
- Where
- 151 sites in United States, Canada and 9 more
- Volunteers
- 2,030 people
- Sponsor
- Astellas Pharma Inc
Overactive Bladder
Painless Laser Therapy for Overactive Bladder
The primary objective of this study is to determine the effectiveness of transvaginally-delivered low level laser therapy (LLLT) versus Sham in the treatment of overactive bladder symptoms in women.
- Trial name
- PLTOAB (NCT01569061)
- Testing
- LCT-1000TM (Manufacturer: LiteCure)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Zipper Urogynecology Associates
Urinary Bladder, Overactive
Transcutaneous Medial Plantar Nerve Stimulation in Women With Idiopathic Overactive Bladder
The investigators conducted a prospective, randomized double-blind, placebo-controlled study based on a placebo technique to evaluate the efficacy of T-MPNS vs placebo in women with idiopathic OAB.
- Trial name
- NCT06390488
- Testing
- Transcutaneous medial plantar nerve stimulation (T-MPNS)
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Pamukkale University
Neurogenic Urinary Bladder Disorder, Urinary Bladder, Neurogenic
Efficacy and Tolerability of Propiverine Hydrochloride in Patients With Neurogenic Detrusor Overactivity
The purpose of this clinical study is to compare efficacy and safety of propiverine hydrochloride extended and immediate release formulations in patients suffering from neurogenic detrusor overactivity.
- Conditions
- Neurogenic Urinary Bladder Disorder, Urinary Bladder, Neurogenic, Bladder Disorder, Neurogenic, Urinary Bladder Disorder, Neurogenic
- Trial name
- NCT01530620
- Testing
- Propiverine hydrochloride ER (extended release), Propiverine hydrochloride IR (immediate release)
- Where
- 3 sites in Austria, Germany and 1 more
- Volunteers
- 66 people
- Sponsor
- APOGEPHA Arzneimittel GmbH
Idiopathic Fecal Incontinence
A Double Blinded Study to Examine the Effect of Alpha Agonist Ointment on Fecal Incontinence in Patients With Idiopathic Fecal Incontinence
The purpose of this study is to assess the effect and safety of alpha agonist ointment on fecal incontinence severity in patients with idiopathic fecal incontinence.
- Trial name
- NCT01421823
- Testing
- alpha agonist ointment
- Where
- Israel
- Sponsor
- RDD Pharma Ltd
Urinary Urge Incontinence
Comparison of Combination Therapy vs Single Agent Therapy for Treatment of Urge Incontinence.
This is a randomized double-blind placebo-controlled clinical trial of posterior tibial nerve stimulation (PTNS) plus extended release oxybutynin versus PTNS alone (placebo pills) in women undergoing treatment of urgency urinary…
- Trial name
- APP (NCT02176642)
- Testing
- Oxybutynin extended release, Posterior Tibial Nerve Stimulation
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Duke University
Overactive Bladder, Overactive Bladder (OAB)
Detrusor Nerve Radiofrequency Ablation for Overactive Bladder in Women
The goal of this clinical trial is to learn if a vaginal radiofrequency (RF) device called MORPHEUSV works to treat overactive bladder (OAB) in women. Researchers also want to learn how safe the device is for this indication.
- Conditions
- Overactive Bladder, Overactive Bladder (OAB), Urge Urinary Incontinence, Mixed Urinary Incontinence (Urge-Predominant)
- Trial name
- DENARA (NCT07209397)
- Testing
- Detrusor nerve radiofrequency ablation
- Where
- 9 sites in United States
- Volunteers
- 202 people
- Sponsor
- InMode MD Ltd.
Overactive Bladder
Safety and Efficacy Study of Intravesical Instillations of BotuGelTM, Slow Release RTGel Based Botox® Formulations, in Idiopathic OAB Patients With Urinary Incontinence ("INTIMO2")
The study will investigate the safety and efficacy of UroGen's TC-3 Gel for sustained release of Botulinum Toxin A (BTX) in urinary bladder in patients with idiopathic overactive bladder.
- Trial name
- INTIMO2 (NCT02674269)
- Testing
- 300 IU of BotuGelTM (60ml), 400 IU of BotuGelTM (60ml), TC-3 Gel
- Where
- 2 sites in Israel
- Sponsor
- UroGen Pharma Ltd.
Stress Urinary Incontinence
A Phase 2 Study of TAS-303 in Female Patients With Stress Urinary Incontinence
The purpose of this study is to evaluate the efficacy and safety of TAS-303 in female patients with stress urinary incontinence.
- Trial name
- NCT04512053
- Testing
- TAS-303 18 mg/day
- Where
- 4 sites in Japan
- Volunteers
- 231 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Urge Incontinence, Overactive Bladder
The Effect of Local Anesthetic Solution in the Bladder Prior to Botox Injections in the Bladder
The purpose of this study is to investigate the effect of Lidocaine solution versus placebo (isotonic Sodium Chloride NaCl) disposed inside the urinary bladder as intravesical anesthesia prior to onabotulinum toxin A injections…
- Conditions
- Urge Incontinence, Overactive Bladder, Anesthesia, Local, Pain, Procedural
- Trial name
- NCT05415865
- Testing
- Alkalinized Lidocaine
- Where
- Denmark
- Volunteers
- 50 people
- Sponsor
- Herlev and Gentofte Hospital
Overactive Bladder
An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB).
This study is designed to evaluate the safety, tolerability, and efficacy of vibegron administered once daily in participants with OAB for up to 52 weeks.
- Trial name
- Empowur (NCT03583372)
- Testing
- Vibegron, Tolterodine Tartrate ER
- Where
- 107 sites in United States
- Volunteers
- 506 people
- Sponsor
- Urovant Sciences GmbH
Overactive Bladder (OAB)
A Phase II Study of KUC-7483 in Patients With Overactive Bladder
To investigate the efficacy and safety of KUC-7483 in overactive bladder patients.
- Trial name
- NCT00742833
- Testing
- KUC-7483
- Where
- 6 sites in Japan
- Volunteers
- 400 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.